TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06543654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omnichroma
Description: Each participants had two kinds of veneers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omnichroma
Description: Each participants had two kinds of veneers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ceram. X Spectra
Description: Ceram. X Spectra

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ceram. X Spectra
Description: Ceram. X Spectra
Study: NCT06188390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided median nerve hydrodissection injection with Hyaluronic acid
Description: Hyaluronic acid was injected under ultrasound guidance around median nerve at the wrist

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided median nerve hydrodissection injection with Dextrose water
Description: Dextrose water was injected under ultrasound guidance around median nerve at the wrist
Study: NCT03867851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBsolvMIR
Description: Study drug IBsolvMIR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Clinical praxis
Study: NCT04866589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distribution of free face masks
Description: Corona hosts will be placed at the entrance of the intervention stores, and hand out face masks to customers entering the store.
Study: NCT05200858

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS - high-dose
Description: Subjects will receive a functional TENS device (delivers 100% of the dose) to wear for 3-5 hours per day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS - high-dose
Description: Subjects will receive a functional TENS device (delivers 100% of the dose) to wear for 3-5 hours per day.
Study: NCT04849130

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Static reconstruction technique according to Schöttle
Description: In static MPFL reconstruction, a graft (harvested autologous gracilis tendon or allogen transplant) is attached to the femoral and patellar bones using tunnels, screws, and/or anchors.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic reconstruction technique according to Becher
Description: Dynamic MPFL procedure by detaching and reinserting only the distal part of a hamstring muscle to the patella and leaving the proximal tendon attached to its muscle. This way the patella position can be adjusted dynamically by hamstring contraction.
Study: NCT05118633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Device and app system designed for participant to self-administer Habit Reversal Training and Stimulus Control
Description: Participants will receive an awareness bracelet and an app that work together to implement key features of Habit Reversal Training and Stimulus Control. The participant will take part in psychoeducation, awareness training, and competing response training related to trichotillomania, as well as receive stimulus control reminders.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Reminder bracelet and journaling app control condition
Description: Participants will receive a bracelet programmed to vibrate randomly several times per hour during waking hours. They will be instructed this is a reminder not to pull. They will also be instructed to journal in an app on their phone several times per day.
Study: NCT06325384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lifelight
Description: Contactless Vital Signs Measurement via RPPG

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure Cuff
Description: Standard Blood Pressure Cuff Digital
Study: NCT06387212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 35 kDa hyaluronan fragment HA35 injection
Description: First, apply an appropriate amount of compound lidocaine cream to the treatment site ( national drug approval number H20063466 ; Beijing Ziguang Pharmaceutical Co., Ltd. ) waited for 60 minutes after applying hemp, and then injected the syringe containing sterile HA35 prepared in advance into the subcutaneous 1.0-1.5mm through the DermaShine PRO negative pressure microneedle importer ( Demasha, South Korea ).
Study: NCT05525403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee Extension Exercise
Description: Participants will be seated in a Steel Flex machine with weight equal to 50% of their 1 repetition maximum added to the machine. Participants will extend the dominant knee until the assigned fatigue level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee Extension Exercise
Description: Participants will be seated in a Steel Flex machine with weight equal to 50% of their 1 repetition maximum added to the machine. Participants will extend the dominant knee until the assigned fatigue level.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quiet Rest
Description: Participants will sit quietly for two minutes, three times.
Study: NCT06218940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY1272
Description: Each patient will receive HY1272 weely or HY1272 weely+Oshitinib 80mg P.O. daily
Study: NCT05965830

Intervention type: DEVICE
Intervention: Diaphragm ultrasound
Description: A single, simultaneous assessment of the diaphragm muscle functioning through dEMG and dUS at the time of spontaneous breathing.
Study: NCT05573503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bring it up - Assessment and support of patients' sexuality in cancer nursing
Description: Participants will attend a five week online university course, Bring it up - Assessment and support of patients' sexuality in cancer nursing. The course addresses theories and models about sexuality in relation to cancer illness, conversation techniques, models for addressing sensitive topics, methods for assessing the impact of cancer on sexuality, methods for preventing and treating sexual problems in relation to cancer, relevant nursing interventions for person-centred counselling about sexuality, and ethical aspects.~The teaching consists of literature, online lectures, seminars, clinical practice, and written exams. A university certificate will be issued to participants who pass all exams.
Study: NCT06204458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mild hyperthermia group
Description: The hyperthermia treatment is carried out in a cycle of two treatments per week, with at least one day in between, over a period of two weeks, according to the manufacturer's instructions. For better tolerability, the application takes place under administration of 10L/min oxygen. According to the guidelines, the rectal (possibly vaginal) temperature (as body core temperature), heart rate and oxygen saturation (Sp02) are continuously determined during the hyperthermia treatment. During the treatment, continuous supervision by trained personnel is guaranteed, and a doctor is on call.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham group
Description: Within the application, patients in the Sham group will undergo a hyperthermia application with virtually no overheating. To achieve this, the patients are positioned on the hyperthermia device in the same way as the intervention group. An insulating foil applied beforehand prevents direct irradiation with water-filtered infrared-A radiation. This prevents an increase in temperature. Due to the insulating blanket and the natural heat from the device and body, patients in the Sham group experience a gentle warmth that cannot be compared with regular whole-body hyperthermia and an increase in core body temperature of around 1.5°C. The number of treatments, the lighting conditions and procedures including 10L/min oxygen supply, is equal to the treatments in the intervention group.
Study: NCT05200858

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS - high-dose
Description: Subjects will receive a functional TENS device (delivers 100% of the dose) to wear for 3-5 hours per day.
Study: NCT04987125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyspnea Neuroscience education
Description: Patients will follow an online therapeutic education course about dyspnea. Education about the cognitive and emotional aspects of dyspnea processing, with the goal of changing maladaptive cognitions and behaviors.~The course will be group-based (5 participants). The frequency will be of 1 session per week for 4 weeks, each session will have a duration of 1 hour.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: General health advice, physiotherapy treatment. The frequency will be of 1 session per week for 4 weeks, each session will have a duration of 1 hour.
Study: NCT05200858

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS - low-dose
Description: Subjects will receive a placebo TENS device (delivers 10% of the dose) to wear for 3-5 hours per day.
Study: NCT04893655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine Hydrochloride
Description: dobutamine infusion will be started at 2mcg/kg/min after min 10 minutes dobutamine infusion will be raised to 5mcg/kg/min
Study: NCT05865509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Escape room
Description: Students were given training on stress response using the escape room method.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Storytelling
Description: Students were given training on stress response using the storytelling method.
Study: NCT04717531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: 400mg, qd, po, day 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 6 mg/kg, day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 6 mg/kg, day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: 420 mg, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 100 mg/m2, day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 100 mg/m2, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90mg/m2, day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 90mg/m2, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2, day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2, day 1
Study: NCT06651359

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Surveys for Quality of Life
Description: This group will take scheduled electronic surveys (at the beginning of the study, months 3, 6, 9, and 12) to assess the overall impact of prostate cancer on quality of life (QoL).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surveys for Quality of Life
Description: This group will take scheduled electronic surveys (at the beginning of the study, months 3, 6, 9, and 12) to assess the overall impact of prostate cancer on quality of life (QoL).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surveys and mHealth App access
Description: This group will take scheduled electronic surveys (at the beginning of the study, months 3, 6, 9, and 12) to assess the overall impact of prostate cancer on quality of life (QoL). Additionally, they will have a brief initial study visit, in-person or virtually, to review the app use. This arm of participants will use the mobile application at home for 12 months. During the first 12 weeks, the application will send daily surveys about symptoms, dietary and physical activities, weekly surveys about their mood, and an assessment of their overall QoL every 3 months. The app will provide tailored educational content, including short readings, videos, and audio recordings, to help users learn more about managing symptoms and improving their functioning. After 12 months of app use, an interview will be conducted to gather feedback about their experiences with the app. The information collected from these interviews will be analyzed to further enhance and improve the app's functionality.
Study: NCT05610319

Intervention type: DRUG
Group type: OTHER
Intervention: Faricimab
Description: Faricimab will be administered via intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab will be administered via intravitreal injection.
Study: NCT06606405

Intervention type: DIAGNOSTIC_TEST
Intervention: scapular dyskinesis test
Description: Scapular dyskinesia in athletes will be visually evaluated. It will be considered present if, during 3 out of 5 arm elevation attempts, any of the following are observed: prominence of the medial or upper scapular border, lower scapular angle, excessive clavicular elevation, or rapid downward rotation of the scapula. After the tester demonstrates the required movements, the athletes will practice the movement. The test will begin with the arms at the sides of the body, elbows straight, and shoulders in neutral rotation. Two testers will observe from behind and video record the movements. Participants will be instructed to raise their arms as high as possible simultaneously, using the \&amp;#39;thumbs up\&amp;#39; position, and to maintain this position for 3 seconds before lowering their arms for another 3 seconds. Athletes will perform the arm elevation with a dumbbell weight calculated as 1.4% of their body weight (Kamonseki, Haik, Ribeiro, Almeida, \&amp;amp; Camargo, 2023).

Intervention type: DIAGNOSTIC_TEST
Intervention: scapular dyskinesis test
Description: Scapular dyskinesia in athletes will be visually evaluated. It will be considered present if, during 3 out of 5 arm elevation attempts, any of the following are observed: prominence of the medial or upper scapular border, lower scapular angle, excessive clavicular elevation, or rapid downward rotation of the scapula. After the tester demonstrates the required movements, the athletes will practice the movement. The test will begin with the arms at the sides of the body, elbows straight, and shoulders in neutral rotation. Two testers will observe from behind and video record the movements. Participants will be instructed to raise their arms as high as possible simultaneously, using the \&amp;#39;thumbs up\&amp;#39; position, and to maintain this position for 3 seconds before lowering their arms for another 3 seconds. Athletes will perform the arm elevation with a dumbbell weight calculated as 1.4% of their body weight (Kamonseki, Haik, Ribeiro, Almeida, \&amp;amp; Camargo, 2023).
Study: NCT06746285

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic Supplement
Description: Participants will be given 1g of a synbiotic product each day, containing 4 microbial strains isolated from an infant gut (total of 1 billion cfu) and a mixture of 4 human milk oligosaccharides. Parents will administer the product by dissolving in breast milk, formula, or water, or mixing with food.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactose (inactive placebo)
Description: Participants will be given 1g of lactose as a placebo. Parents will administer the product by dissolving in breast milk, formula, or water, or mixing with food.
Study: NCT06760520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivonescimab (SMT112 or AK112) Injection
Description: Eligible subjects will receive short-course radiotherapy (SCRT), 25Gy/5f/1 week. 1-2 weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK112 20 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 850-1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
Study: NCT06247774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation
Description: Participation in a 12-week cardiac rehabilitation program

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: Participants will receive regular phone calls in place of cardiac rehabilitation visits
Study: NCT05157581

Intervention type: DEVICE
Intervention: Extracorporeal photopheresis (ECP)
Description: Extracorporeal photopheresis is a process that exposes a collection of white blood cells and plasma to a light sensitizing agent, methoxsalen, and returns that compartment to the body.

Intervention type: DRUG
Intervention: Methoxsalen Injection
Description: Methoxsalen is a light-sensitizing sterile compound added to the collected white blood cells and plasma during ECP.
Study: NCT06115330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Press Needle Acupuncture
Description: Ear acupuncture using Pyonex press needles were installed with a diameter of 0.17mm, 0.9mm deep. The needles were retained for three days and stimulated at the installation site of the patch needle by means of pressure on the acupuncture point ears that have been attached needles on both sides, 1 minute at each point, four times a day, for 3 consecutive days and the patch was removed on the 3rd day
Study: NCT05323617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Administered as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Administered as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin
Description: Horse or rabbit antithymocyte globulin administered as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Administered orally.
Study: NCT06018792

Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular Culture
Description: PCR based bacterial profiling technique, that creates a differentiating microbial signature based on amplification of the interspace region in bacterial ribosomal RNA. Results on gel capillary electrophoresis are analyzed with software to recognize these signatures.

Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular Culture
Description: PCR based bacterial profiling technique, that creates a differentiating microbial signature based on amplification of the interspace region in bacterial ribosomal RNA. Results on gel capillary electrophoresis are analyzed with software to recognize these signatures.

Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular Culture
Description: PCR based bacterial profiling technique, that creates a differentiating microbial signature based on amplification of the interspace region in bacterial ribosomal RNA. Results on gel capillary electrophoresis are analyzed with software to recognize these signatures.

Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular Culture
Description: PCR based bacterial profiling technique, that creates a differentiating microbial signature based on amplification of the interspace region in bacterial ribosomal RNA. Results on gel capillary electrophoresis are analyzed with software to recognize these signatures.
Study: NCT06154343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GQ1005
Description: an antibody drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GQ1005
Description: an antibody drug conjugate
Study: NCT05213195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKG2D CAR-NK
Description: NKG2D CAR-NK infusion through peritoneal in stage 1 and later combined with intra venous in stage 2.
Study: NCT04676425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: Administered at a dose of 4 mg via oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: Administered at a dose of 4 mg via oral tablet
Study: NCT06398483

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical fixation of acute bony mallet finger
Description: surgical fixation of acute bony mallet finger by micro plate will be performed under either Infraclavicular nerve blockage or digital block will be performed in all patients .fracture fragment will be reduced, The legs of the plate will be embedded in the terminal tendon to grasp the fragment. The plate will be fixed to the distal phalanx with a 1.3-mm screw.~surgical fixation of acute bony mallet finger by blocking K.wire will be performed under either infraclavicular nerve block or digital block. The injury will be surgically intervened with an extensor blocking k.wire. the distal phalanx was extended to maximum flexion and (K.wire) will be placed in the cephalic direction through the terminal band at an angle of 45 degrees to the mid-phalanx. Reduction of the fracture fragment will be achieved by bringing the distal phalanx to extension . the DIP will be transfixed with a second K-wire

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical fixation of acute bony mallet finger
Description: surgical fixation of acute bony mallet finger by micro plate will be performed under either Infraclavicular nerve blockage or digital block will be performed in all patients .fracture fragment will be reduced, The legs of the plate will be embedded in the terminal tendon to grasp the fragment. The plate will be fixed to the distal phalanx with a 1.3-mm screw.~surgical fixation of acute bony mallet finger by blocking K.wire will be performed under either infraclavicular nerve block or digital block. The injury will be surgically intervened with an extensor blocking k.wire. the distal phalanx was extended to maximum flexion and (K.wire) will be placed in the cephalic direction through the terminal band at an angle of 45 degrees to the mid-phalanx. Reduction of the fracture fragment will be achieved by bringing the distal phalanx to extension . the DIP will be transfixed with a second K-wire
Study: NCT05064787

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Digital Health Coaching
Description: The digital health coaching program consists of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application. The program is 6-months in duration and designed for engagement following CAR T cell infusion.
Study: NCT06067828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate
Description: Randomized participants will receive 2 inhalations of BGF MDI via oral inhalation twice daily (BID).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment B: Budesonide and Formoterol Fumarate
Description: Randomized participants will receive 2 inhalations of BFF MDI via oral inhalation BID.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment C : Placebo
Description: Randomized participants will receive 2 inhalations of placebo MDI via oral inhalation BID.
Study: NCT06286124

Intervention type: PROCEDURE
Intervention: Hybrid Surgery
Description: Hybrid incisional hernia repair, as described by Van den Dop et al. (2021)
Study: NCT05796752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Cognition-enhancing medication

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ComB Behavioral Therapy
Description: Therapy for BFRBs